On the 14th of january 2013, the APC-PCI patent will be settled.

The EPO has summoned for oral proceedings, as they declare that the present application is missing a vital piece.

EPO declares that since the application is missing a crucial cut-off value, it is as such useless.

Bioporto on the other hand finds the application to be fulfilling all the relevant rules.

The oral proceedings will settle this dispute, and will decide if Bioporto will hold its first US/EU patent, or if they will have to settle on holding the US patent on the use of APC-PCI as a marker for the selection of patients with severe sepsis.

Read the decision on why EPO calls for a summon.

APC-PCI oral proceedings

About Karl M. Bidstrup

Tidligere ejer af Medicoinvestor.com Strategien har gennem mange år været at profitere på etablerede aktier, og brænde det hele af på Bioporto... Sad but true. Kontakt mig på medicoinvestor(A)gmail.com hvis du har en million du ikke ved hvor du skal gemme, så skal jeg nok holde den for dig. :-)

 

One Response to The APC-PCI patent dispute will settle at oral proceedings.

  1. Så er Oral proceedings aflyst efter telefonsamtalen den 26/11, hvilket vil sige at Bioporto formentlig står med det første EPO/USPTO patent inden længe.

    Jamen så kan vi jo sige goddag til Eli Lilly igen….

What do you say?

Set your Twitter account name in your settings to use the TwitterBar Section.